AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02513160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate via 320 mcg BAI
Description: Beclomethasone dipropionate treatment administered via breath-actuated inhaler (BAI) (320 mcg/day).
Study NCT02513160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent during the run-in and double-blind study periods.
Study NCT01697397 — intervention group
Intervention type: DEVICE
Intervention: Recording of Myoelectric Signals
Description: Obtain recordings of the electrical signals of the gut.
Study NCT02986152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer Distress Coach Mobile App
Description: Cancer Distress Coach is a stand-alone symptom management tool with three basic components. The Learn about Distress module provides psycho-education. The Insights module includes an inspiring Quote of the Day, daily activity planning tips, a graph displaying the user's distress level plotted over time, and assessment feedback. The main action of the application is in the Activities module that provides patients with skills to manage their stress in the moment they experience it. Depending on the severity, the patient is routed to any of a number of helpful skills based on cognitive-behavioral principles. The stress management tools include positive imageries, soothing songs and pictures, and the Relax-Identify-Decide tool. Also included is find support and get support now to connect the user to his/her support network and locate informal cancer and non-cancer related support or (immediate) professional care.
Study NCT00583726 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: written materials only
Description: dietary guidance materials and pedometers
Study NCT02986152 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cancer Distress Coach Mobile App
Description: Cancer Distress Coach is a stand-alone symptom management tool with three basic components. The Learn about Distress module provides psycho-education. The Insights module includes an inspiring Quote of the Day, daily activity planning tips, a graph displaying the user's distress level plotted over time, and assessment feedback. The main action of the application is in the Activities module that provides patients with skills to manage their stress in the moment they experience it. Depending on the severity, the patient is routed to any of a number of helpful skills based on cognitive-behavioral principles. The stress management tools include positive imageries, soothing songs and pictures, and the Relax-Identify-Decide tool. Also included is find support and get support now to connect the user to his/her support network and locate informal cancer and non-cancer related support or (immediate) professional care.
Study NCT03705169 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAR441236
Description: Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
Study NCT02513160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albuterol/salbutamol
Description: Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent during the run-in and double-blind study periods.
Study NCT03821311 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed tomography
Description: End-inspiratory/end-expiratory CT is repeated 3 times corresponding to the 3 studied conditions: At baseline, through expiratory resistive loading using an adjustable PEP mask, and after 5 min of nasal high flow therapy at 25 L/min.
Study NCT02513160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albuterol/salbutamol
Description: Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent during the run-in and double-blind study periods.
Study NCT02513160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone dipropionate via 320 mcg MDI
Description: Beclomethasone dipropionate treatment administered via metered-dose inhaler (MDI) (320 mcg/day).
Study NCT03972904 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Light-Fat Rice® combined with Active Peptide®+ lifestyle guidance
Description: Subjects will be given the Light-Fat Rice® combined with Active Peptide® with a lifestyle guidance to assist diabetes management. The method of taking the product has two parts: 1.Light-Fat Rice®: 80g (1 pack) per day as a staple meal replacement, used as a separate staple food or mixed with other staple foods, taking 4 weeks; 2.Active Peptide®: 20g (2 packs) per day (1 pack each morning and evening), served with 300ml of 40°C warm water each time before meals and take it for 4 weeks.
Study NCT03972904 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin + lifestyle guidance
Description: A staple food of comparable energy containing a small amount of dietary fiber combined with a comparable energy maltodextrin (both produced by the same manufacturer) with a lifestyle guidance will be given by the professional to assist in diabetes management. The product is taken as follows: 1.equal-energy staple food containing a small amount of dietary fiber: 80g (1 pack) per day, used as an independent staple food or mixed with other staple foods, taking for 4 weeks; 2.equal-energy maltodextrin: 20g(2 packs) per day(1 pack each morning and evening),take it with 300ml of 40°C warm water for 4 weeks.
Study NCT04600765 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: hsCRP serum measurement of inflammation
Description: hsCRP inflammation change as result of non-contaminated diet
Study NCT00607451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu-120
Description: Capsules of 300, 900 and 2700mg; administered as a single dose with a one week washout between each administration.
Study NCT03497325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: autologus platelet rich plasma
Description: 55 participant unergoing prelabor primary CS will receive intramyometrial injection of PRP after closure of uterine incision
Study NCT03497325 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 55 participant unergoing prelabor primary CS will receive intramyometrial injection of normal saline after closure of uterine incision
Study NCT03684018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IgPro10
Description: Normal human immunoglobulin G administered intravenously
Study NCT00413153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atazanavir/ritonavir
Description: atazanavir 300mg + ritonavir 100mg once daily
Study NCT00413153 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lopinavir/ritonavir
Description: patient remains on their pre-study dose of lopinavir/ritonavir
Study NCT00794573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: 0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
Study NCT00794573 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
Study NCT03705169 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous (IV) infusion(s) or subcutaneous (SC) injection(s)
Study NCT02555059 — intervention group
Intervention type: DRUG
Intervention: Cipro (Ciprofloxacin, BAYQ3939)
Description: Treatment parameters following the physician's decision based on the summary of product characteristics.
Study NCT01879800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy plus Illness Management
Study NCT04598672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for insomnia (CBTi)
Description: Patients will undergo a 7 sessions course in cognitive behavioral therapy for insomnia.
Study NCT01091376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150mg/day
Study NCT01091376 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: 60-70Gy/30-35f
Study NCT02344134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP607
Description: 0.5 mL, intramuscular, a single dose
Study NCT02344134 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Agrippal S1
Description: 0.5 mL, intramuscular, a single dose
Study NCT02431884 — intervention group
Intervention type: PROCEDURE
Intervention: collect body fluids/tissues & med history
Description: collect tissues/fluids \& history
Study NCT03951870 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neuromodulation via fMRI Neurofeedback task
Description: Two active neurofeedback groups will practice to up regulate their designated neural targets via identical experimental protocol (varying only the origin of the feedback).
Study NCT03951870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromodulation via fMRI Neurofeedback task
Description: Two active neurofeedback groups will practice to up regulate their designated neural targets via identical experimental protocol (varying only the origin of the feedback).
Study NCT03951870 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccination
Description: Subjects will be vaccinated against Hepatitis B
Study NCT03951870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination
Description: Subjects will be vaccinated against Hepatitis B
Study NCT03951870 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hepatitis B vaccination
Description: Subjects will be vaccinated against Hepatitis B
Study NCT03156270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivaer Stylus
Description: Stylus used to deliver low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
Study NCT03209830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OSU 6162
Description: All patients will receive a dose of OSU6162 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
Study NCT03209830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: All patients will receive a dose of placebo 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
Study NCT03998085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib hydrochloride capsule 12 mg, orally, once a day, oral before breakfast, according to the research program for 2 weeks, discontinued for 1 week. Patients with complete remission (CR), partial remission (PR) and stable disease (SD) continued to administer drugs until the disease progressed, intolerable toxicity or withdrawal was required. Patients with progression of illness (PD) discontinued their medication.
Study NCT03719183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Conventional Cytogenetics Studies
Description: Metaphase cytogenetic studies will be performed in all cases according to standard methods. Chromosome preparations will be G-banded using trypsin and Giemsa, and karyotypes will be described according to the International System for Human Cytogenetic Nomenclature (ISCN) 2016.
Study NCT03719183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescent in Situ Hybridization (FISH) Panels
Description: AML Panel includes:~* t(8;21) (RUNX1-RUNX1T1).~* inv(16), t(16;16) (CBFB-MYH11).~* t(9;22) (BCR-ABL).~* 11q23 KMT2A rearrangements.~* inv(3) MECOM rearrangements.~* DEK-NUP214 rearrangements.~* Del(5q) Deletion~* Del(7q) Deletion~Acute Promyelocytic Leukemia panel includes:~* t(15;17) (PML-RARA).~* 17q RARA rearrangements
Study NCT03719183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Multiplex FISH (M-FISH)
Description: 24-color karyotyping
Study NCT00096382 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: aldesleukin
Description: high dose: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days (maximum 5 doses) or low dose: 250,000 IU/kg subcutaneously daily for 5 days, after a two day rest, 125,000 IU/kg subcutaneously daily for 5 days for five weeks (2 days rest per week)
Study NCT00096382 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: filgrastim
Description: 10 mcg/kg/day daily subcutaneously until neutrophil count >1x10\^9/1.
Study NCT00096382 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: therapeutic tumor infiltrating lymphocytes
Description: Lymphocytes that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient.
Study NCT00096382 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclophosphamide
Description: 60 mg/kg/day x 2 days intravenously over 1 hour
Study NCT00096382 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: fludarabine phosphate
Description: 25 mg/m\^2/day intravenous piggyback daily over 15-20 minutes for 5 days
Study NCT00096382 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Description: Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.
Study NCT04174599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: F-627
Description: Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein
Study NCT04174599 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: F-627
Description: Recombinant Human Granulocyte Colony Stimulating Factor-Fc Fusion Protein
Study NCT01931436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qing'E pill
Description: Qing'E pill is composed of eucommia, psoralen, walnuts and garlic.
Study NCT03447925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medicinal Plant
Description: Medicinal Plant Extract with vaseline cream
Study NCT03447925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salicylate
Description: Salicylate 10% with vaseline cream
Study NCT03447925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaseline
Description: Vaseline cream
Study NCT02447211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxepin cream 5%
Description: Patients use doxepin creamtwice daily for one weeks
Study NCT02447211 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients use cream without doxepin ingredient twice daily for one weeks
Study NCT02614326 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autobiographical Memory Flexibility (MemFlex) training
Description: As in experimental arm description
Study NCT02614326 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducation
Description: As in experimental arm description
Study NCT03525405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: napabucasin
Description: Single 240 mg dose containing 100 μCi of 14C-napabucasin will be administered with 240 mL of water following an overnight fast.
Study NCT02838823 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanized anti-PD-1 monoclonal antibody toripalimab
Description: humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
Study NCT03252535 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellavita HD lower dose
Description: The participants will receive a total of 9 intravenous administrations of 1x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
Study NCT03252535 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellavita HD higher dose
Description: The participants will receive a total of 9 intravenous administrations of 2x10\^6 cells/weight range divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
Study NCT03187483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic treatment
Description: orthodontic treatment in maxillary crowding
Study NCT02808806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: real-time audio-visual feedback
Description: real-time audio-visual feedback to caregivers on TSD (i.e. displaying time, a colour code which will provide an easy-view visualization on whether or not pre-set median time delays between locations are exceeded, and auditory signals indicating the elapsed time), displayed through handhelds and on pre-mounted tablets through the whole trajectory of acute stroke care
Study NCT01208402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: Infusion will be started at 50 mcg/kg/min for 4 minutes and titrated in increments of 50 mcg/kg/min up to a maximum of 300mcg/kg/min (maintenance dose) to maintain a heart rate between 60 and 80 beats per minute (bpm) while maintaining a minimum systolic blood pressure (SBP) of 95 mmHg during the length of surgery and up to 12 hours post-operatively.
Study NCT01757769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: 8 mg daily for 24 weeks
Study NCT01169467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-Care plus Dexmedetomidine
Description: Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment
Study NCT01169467 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard-of-Care
Description: Subjects who are treated with the standard of care sedation regiment only.
Study NCT01208402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: Infusion will be started at 50 mcg/kg/min for 4 minutes and titrated in increments of 50 mcg/kg/min up to a maximum of 300mcg/kg/min (maintenance dose) to maintain a heart rate between 60 and 80 beats per minute (bpm) while maintaining a minimum systolic blood pressure (SBP) of 95 mmHg during the length of surgery and up to 12 hours post-operatively.
Study NCT02479412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800 μg AZD7594 once daily
Description: Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
Study NCT03252535 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive a total of 9 intravenous administrations of placebo divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
Study NCT02479412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 µg AZD7594 once daily
Description: Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
Study NCT01505595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Description: 12 weeks
Study NCT01505595 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham proprioceptive training
Description: Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
Study NCT01186783 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ivabradine
Description: Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.~Day 1 and 2:~5,0 mg ivabradine b.i.d. if heart rate ≥60bpm (acute renal failure: ≥70bpm)~Day 3 and 4:~5,0 mg ivabradine b.i.d. if 60bpm≥heart rate\<90bpm (acute renal failure: 70bpm≥heart rate \<90bpm~7,5 mg ivabradine b.i.d. if heart rate ≥90bpm
Study NCT01499927 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electronic reminders
Description: Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
Study NCT02997956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.
Study NCT02997956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter Arterial Chemoembolization
Description: Minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
Study NCT02891564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Band Together
Description: a mobile 3D video game that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms. This game is analogous to Project: EVO.